About HQL Dividend Returns
Tekla Life Sciences Investors (HQL) is a dividend-paying stock. When dividends are reinvested through a DRIP (Dividend Reinvestment Plan), they purchase additional shares, which then generate their own dividends—creating a compounding effect that can significantly boost long-term returns.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of HQL over the past year?
Tekla Life Sciences Investors (HQL) delivered a total return of 63.64% over the past year when dividends are reinvested. The price-only return was 47.69%, meaning dividends contributed an additional 15.95 percentage points to total returns.
Q2How much would $10,000 invested in HQL be worth today?
A $10,000 investment in Tekla Life Sciences Investors one year ago would be worth $16,364 today with dividends reinvested (DRIP). Without reinvesting dividends, the same investment would be worth $14,769. Dividend reinvestment added $1,595 to the portfolio value.
Q3Does HQL pay dividends?
Yes, Tekla Life Sciences Investors (HQL) pays dividends. In the last year, HQL paid approximately $1.10 per share in dividends (5.69% yield). Reinvesting these dividends through a DRIP can significantly boost long-term returns — over 20+ years, dividend compounding can account for 30–50% of total returns for dividend-paying stocks.
Q4Did HQL beat the S&P 500?
Yes, Tekla Life Sciences Investors (HQL) outperformed the S&P 500 by 42.80 percentage points over the past year. HQL delivered a total return of 63.64%, compared to the S&P 500's 20.84%. This 42.80pp alpha means investors in HQL earned more than a passive S&P 500 index fund.
Q5What is HQL's worst drawdown?
Tekla Life Sciences Investors (HQL) experienced a maximum drawdown of -10.59% over the past year, declining from its peak on 2025-10-31 to its trough on 2026-03-06. The stock recovered to its prior peak by 2026-04-14. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is HQL's long-term total return over 10, 20, or 30 years?
Here are Tekla Life Sciences Investors (HQL)'s long-term returns with dividends reinvested. Over 10 years, the total return is 103.5% (7.4% CAGR) — $10,000 would have grown to $20,347. Over 20 years: 228.5% total return (6.1% CAGR) — $10,000 → $32,849. Over 30 years: 341.9% total return (5.1% CAGR) — $10,000 → $44,187. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was HQL's best and worst year?
Tekla Life Sciences Investors's best calendar year was 1999 with a total return of 63.3%. Its worst year was 2002 with a total return of -44.6%. This range shows the volatility investors should expect — the difference between the best and worst year is 107.8 percentage points.
Find the Best Total Return Stocks
Screen for dividend stocks with the strongest long-term returns, including DRIP compounding.
How much would $100/month in HQL be worth today?
Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds
HQL outperformed the S&P 500 by 
HQH
XBIO
GHC
BMRN
AMGN
GILD
REGN
VRTX
BIIB
ILMN